Rational combination strategies, including association with chemotherapy, immune checkpoint inhibitors (to enhance tumor immunogenicity and bypass immune evasion), and dual degraders or PROTACs (to selectively degrade MDM2 and potentially overcome resistance and toxicity), may improve the efficacy and durability of response to MDM2 inhibitors. The gene discussed is MDM2; the disease is neoplasm.